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The molecular pathogenesis of gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) remains to be elucidated. High-
mobility group A (HMGA) proteins play important roles in the regulation of transcription, differentiation, and neoplastic
transformation. In this study, the expression of HMGA1 and HMGA2 was studied in 55 GEP NETs. Overexpression of HMGA1 and
2 was frequently detected in GEP NETs compared with normal tissues. Nuclear immunostaining of HMGA1 and 2 was observed in
GEP NETs (38 of 55, 69%; 40 of 55, 73%, respectively). High-mobility group A2 expression increased from well-differentiated NET
(WNET) to well-differentiated neuroendocrine carcinoma (WNEC) and poorly differentiated NEC (PNEC) (Po0.005) and showed
the highest level in stage IV tumours (Po0.01). In WNECs, the expression of HMGA1 and 2 was significantly higher in metastatic
tumours than those without metastasis (Po0.05). Gastroenteropancreatic NETs in foregut showed the highest level of HMGA1 and
2 expressions. MIB-1 labelling index (MIB-1 LI) correlated with HMGA1 and 2 overexpression (R¼0.28, Po0.05; R¼0.434,
Po0.001; respectively) and progressively increased from WNETs to WNECs and PNECs (Po0.001). Let-7 expression was
addressed in 6 normal organs, 30 tumour samples, and 24 tumour margin non-tumour tissues. Compared with normal tissues, let-7
downregulation was frequent in NETs (19 of 30, 63%). Higher expression of HMGA1 and 2 was frequently observed in tumours with
let-7 significant reduction (53, 42%, respectively). The reverse correlation could be detected between HMGA1 and let-7 (Po0.05).
Our findings suggested that HMGA1 and 2 overexpression and let-7 downregulation might relate to pathogenesis of GEP NETs.
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Although the gastrointestinal (GI) tract and pancreatic organ have
the largest population of endocrine cells, gastroenteropancreatic
(GEP) neuroendocrine tumours (NETs) are rare with an age-
adjusted annual incidence of 2.5–4.5 per 100000 (Maggard et al,
2004). However, their incidence is increasing by approximately 6%
per year (Gustafsson et al, 2008). Gastroenteropancreatic NETs
comprise a heterogeneous group of neoplasms arising from the
diffuse neuroendocrine system and are divided by their embryo-
logical site of origin into foregut, midgut, and hindgut tumours
(Maggard et al, 2004). These tumours strongly differ from each
other on the basis of different pathogenetic, clinical, functional,
histological, and prognostic patterns (Klo ¨ppel et al, 2004). The
molecular mechanisms of GEP NETs tumourigenesis are poorly
understood (Zikusoka et al, 2005).
The high-mobility group A (HMGA) proteins are non-histone
chromosomal proteins that bind through their AT-binding motifs
to the minor groove of AT-rich DNA strands. They have no
intrinsic transcriptional activity but can modulate transcription by
altering chromatin architecture (Reeves and Nissen, 1990; Thanos
and Maniatis, 1992; Thanos et al, 1993). The two types of HMGA
protein, HMGA1 and HMGA2, have similar functions and are
encoded by two different genes at chromosomal loci 6p21.3 and
12q15, respectively (Johnson et al, 1989). High-mobility group A
proteins are widely expressed during embryogenesis, whereas their
expression is low or absent in normal adult tissues (Zhou et al,
1995; Chiappetta et al, 1996). High-mobility group A proteins are
involved in many diverse biological processes such as regulation of
transcription, embryogenesis, differentiation, neoplastic trans-
formation, and integration, and expression of viral genomes
(Sgarra et al, 2004). Both HMGA1 and 2 proteins are overexpressed
in several experimental and human malignancies. Overexpression
of HMGA1 has been noted in different cancer types and it has been
recognised as a good target for therapeutic intervention in
pancreatic cancer. High-mobility group A2 overexpression is a
hallmark of various benign and malignant tumours and is also
associated with a highly malignant phenotype and is a poor
prognostic index (Fusco and Fedele, 2007). However, there is no
study to detect HMGA proteins expression and to evaluate their
role in GEP NETs.
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sThe microRNAs (miRNA), a family of mature noncoding small
RNA 21–25 length nucleotides, have been shown to play a role in a
variety of biological processes. They regulate gene expression at the
posttranscription level by direct cleavage of a target mRNA using
interference machinery (mRNA cleavage) or by inhibition of protein
synthesis (Caldas and Brenton, 2005; Esquela-Kerscher and Slack,
2006). Recent evidence has shown that miRNA misexpression
correlates with various human cancers and indicated that some
miRNAs can function as oncogenes or tumour suppressors (Esquela-
Kerscher and Slack, 2006). Several studies reported that HMGA2 is
negatively regulated by the let-7 miRNA family in a mouse model
system (Mayr et al, 2007), in head and neck cancers (Hebert et al,
2007), in uterine leiomyomas (Wang et al, 2007), in lung cancer cell
lines (Lee and Dutta, 2007), and in ovarian cancers (Shell et al, 2007).
By computer searches (TargetScan, TargetScanS, PicTar, and
miRNAviewer), HMGA1 can also be potentially regulated by let-7.
To our knowledge, there are few reports about miRNA expression in
GEP NETs and no investigation about the relations between HMGA1
and 2 proteins expression and the let-7 expression in GEP NETs.
In this study, we investigated the prevalence of HMGA1 and 2
involving in different GEP NETs and assessed its relevance to
malignancy. We performed a systematic analysis of immunohis-
tochemistry and reverse transcription (RT)–PCR for HMGA1 and
2 expression in a series of GEP NETs from different sites. Let-7 was
also analysed by semiquantitative RT–PCR. The data were then
correlated with relevant clinical information. In addition, we
investigated possible associations between HMGA1, 2 expression
and let-7 expression.
MATERIALS AND METHODS
Patients and samples
Fifty-five paraffin-embedded surgical or biopsy specimens were
collected (from the surgical pathology files of the Department of
Pathology, University of Tokushima School of Medicine, and the
affiliated hospitals) from patients affected by NETs of GEP from
1982 to 2007. Tumours of the GEP tract were from foregut:
esophagous (n¼1), stomach (n¼11), pancreas (n¼11), duode-
num (n¼6); midgut: ileum (n¼2), appendix (n¼1); hindgut:
colon (n¼5), rectum (n¼14); liver metastasis (n¼1); and lymph
node metastasis (n¼3). The frequency of GEP NETs in this study
is general agreement with published reports from the Neuroendo-
crine Tumour Workshop of Japan (Ito et al, 2007). Notably, the
frequency of midgut NETs was very low. Paraffin sections were
stained with pan-NE markers, such as chromogranin A and
synaptophysin, to confirm the NE immunophenotype. The
diagnosis of NETs was made on the basis of morphological and
immunohistochemical findings evaluated by two independent
pathologists (ZRQ and TS), according to the World Health
Organization classification (Klo ¨ppel et al, 2004). These included
well-differentiated NET (WNET, of either benign or uncertain
behaviour; n¼29), well-differentiated NEC (WNEC; n¼13), and
poorly differentiated NEC (PNEC; n¼13). The tumour stage was
made on the basis of the recently published TNM classification
system (Rindi et al, 2006; Rindi et al, 2007). Patient characteristics
for these cases are summarised in Table 1.
Immunohistochemistry
High-mobility group A1, HMGA2, and Ki-67 antigen immunolo-
calisation based on the labelled streptavidin-biotin method were
performed on sections from representative blocks of paraffin-
embedded tissues. After deparaffinisation and antigen retrieval
using an autoclave oven technique, sections were incubated at 41C
overnight with goat polyclonal anti-HMGA1 antibody (1:50;
Santa Cruz Biotech, Santa Cruz, CA, USA) and goat polyclonal
anti-HMGA2 antibody (1:50; Santa Cruz Biotech) or with Ki-67
antigen mouse monoclonal antibody (1:100, DakoCytomatin,
Glostrup, Denmark). Antigen–antibody complexes were detected
using the cobalt-3, 30-diaminobenzidine (Co-DAB) reaction.
Squamous cell carcinomas known to be positive for HMGA1 and
2 were used as positive control. Sections incubated in PBS without
the primary antibody served as negative controls. Owing to the
absence of tissue entirely composed of neuroendocrine cells,
several whole normal human organs were used as controls:
oesophagus, stomach, duodenum, appendix, small intestine,
pancreas, colon, and rectum. Clear nuclear staining was considered
to present a positive stain for HMGA1, 2, and Ki-67. A total of
200–1000 cells were counted and the percentage of HMGA1-,
2-stained tumour cells was scored on a scale of 0–3 (0: no
expression; 1þ: 1–10%; 2þ: 10–50%; 3þ: 450%). The Ki-67
antigen labelling index (LI) was determined by counting the
number of positive cells in a total of 200–1000 tumour cells
observed in several representative high-power fields ( 400).
Microdissection and RNA isolation
From each paraffin block of representative tumour areas, serial
sections with a thickness of 10mm were prepared and stained with
nuclear Fast Red (Sigma-Aldrich, Tokyo, Japan). Malignant cells
were selected under microscope magnification ( 20 to  100)
and dissected from the slide using a scalpel or Laser microdissec-
tion (Molecular Machines & Industries, Glattbrugg, Switzerland).
Total RNA was isolated using the high pure RNA paraffin kit
(Roche Diagnostics GmbH, Mannheim, Germany) as per the
manufacturer’s instructions. Extracted RNA concentration and
purity were measured using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Del, Wilmington, DE,
USA) and by PCR using the primer pair specific for GAPDH with
or without RT, followed by 1% agarose gel electrophoresis and
ethidium bromide staining.
RT–PCR analysis for HMGA1 and 2
Total RNA (500ng) was reverse transcribed, using random
hexanucleotides as primers (50pM) and 200 units primescript
reverse transcriptase (Takara Bio Inc., Otu, Japan). The cDNA was
amplified in a 20ml reaction mixture containing 0.2mM dNTP,
1.0mM MgSO4, 0.5mM each primer and 1U KOD-Plus polymerase
(Toyobo, Osaka, Japan). After a denaturing step (951C for 2min),
the cDNA was further amplified in 35 PCR cycles (951C for 1min,
581C for 30s, and 681C for 30s). The following primers were used
to amplify the HMGA1 transcript: forward primer, 5-AGAG
ACCTCGGGGCCGACCA-3; reverse primer, 5-GATGCCCTCCTC
TTCCTCCTT-3. The following primers were used to amplify the
HMGA2 transcript: forward primer, 5-ACTTCAGCCCAGGGAC
AAC-3, which maps onto the first exon; reverse primer, 5-GCT
GCTTTAGAGGGACTCTTGTT-3, which maps onto the second
exon. Expression of the GAPDH gene was used as an internal
control for the amount of cDNA tested. The reaction products were
analysed on a 2% agarose gel. Total RNA samples from several
whole normal human organs were used as controls: oesophagus,
stomach, duodenum, appendix, small intestine, pancreas, colon,
and rectum.
Semiquantitative RT–PCR analysis for let-7
The expression of human mature let-7 (hsa-let-7) miRNA was
analysed using a mirVana quantitative RT–PCR miRNA detection
kit (Ambion, Austin, TX, USA, Cat. nos. AM1558 and AM30000)
according to the manufacturer’s protocol. Ubiquitously expressed
U6 small nuclear RNA (Ambion, Cat. No. AM30303) was used for
normalisation and as an internal control. Briefly, RT–PCR was
performed with 20ng of total RNA using gene-specific RT primers.
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scDNA was generated. The PCR consisted of 32 cycles (951Cf o r1 5s ,
601C for 30s) after an initial denaturation step (951Cf o r3m i n ) .T h e
PCR products were analysed by electrophoresis on 2% agarose gels.
Quantitation of let-7 expression levels was achieved by densitometric
scanning of ethidium bromide-stained gels. The levels of expression
of let-7 w a sa n a l y s e dw i t hc o m p u t e rs o f t w a r e( I m a g e ,N I H )a n d
shown as the ration of let-7 to U6 (Qian et al, 2005).
Statistical analysis
To determine the significance of associations between different
variables, data were statistically analysed by Mann–Whitney
U-test, Kruskal–Wallis test, w
2–test, and Spearman’s correlation
coefficient using StatView J-4.5 software (Abacus Concepts,
Berkeley, CA, USA). A P-value of less than 0.05 was considered
statistically significant.
RESULTS
HMGA1 and 2 expression analysis by IHC
Immunolocalisation of HMGA1, 2 proteins was mainly nuclear.
However, cytoplasmic staining was observed similar to that
reported earlier for placental extravillous trophoblast and lung
cancer, but was found to be nonspecific background staining and
was ignored (Sarhadi et al, 2006).
In general, there were no HMGA1 and 2 expressions in the
normal organs including oesophagus, stomach, duodenum,
appendix, small intestine, pancreas, colon, and rectum. In GEP
normal NE cells, detected by choromgranin A (Figure 1A–E),
HMGA1 and 2 were immunostained negatively (Figure 1F–O).
In GEP NETs, a high proportion of tumours (38 of 55, 69%) was
detected with nuclear HMGA1 protein expression (Figure 2E–H,
Tables 1 and 2). Twenty-seven (49%) tumours showed a high
expression (3þ and 2þ), 13 (24%) tumours showed a low
expression (1þ), and 17 (31%) tumours were immuno negative.
According to different histopathologic categories, HMGA1 over-
expression was detected in 21/29 (72%) of WNETs, 8/13 (61%) of
WNECs and 9/13 (70%) of PNECs (Table 2). This HMGA1 protein
expression did not show a significant difference level among
WNETs, WNECs and PNECs (Figure 3A). However, NETs in
foregut showed the highest level of HMGA1 expression even it was
not significant (Figure 3C).
A clear nuclear staining for HMGA2 was detected in 40 of 55
(73%) GEP NETs (Figure 2I–L, Tables 1 and 2). Twenty-five of
these (46%) showed a high expression (3þ and 2þ) of HMGA2,
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Colon
Figure 1 Choromgranin A immunostaining detected normal neuroendocrine (NE) cells in each organ showed cytoplasmic immunoreactions (A–E).
High-mobility group A1 (HMGA1) (F–J) and HMGA2 (K–O) showed negative immunoreaction in normal NE cells and other normal cells of each organ.
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sand 15 (27%) tumours showed low expression (1þ), and 15 (27%)
tumours were negative immunoreactions (Table 2). According to
different histopathologic categories, HMGA2 protein expression
progressively increased from WNET to WNEC and PNEC, and the
significant increasing was detected between WNET and PNEC
(Po0.005) (Figure 3B). Neuroendocrine tumours of foregut
showed the frequent HMGA2 overexpression and highest level of
HMGA2 expression (Po0.05) (Table 2, Figure 3D).
In WNECs, the expression of HMGA1 and 2 was significantly higher
in metastatic tumours than in tumours without metastasis (Po0.05,
Po0.05; respectively; Figure 3E and F). This tendency is not clear in
PNECs. In addition, HMGA2 showed the highest level in stage IV GEP
NETs (stage IV vs stages I, II, III, Po0.01; Figure 3H). High-mobility
group A1 expression was also higher in stage IV tumours than stages I,
II, and III tumours, but it was not significant (Figure 3G).
We also investigated the correlation between MIB-1 labelling
index (MIB-1 LI), which was assessed earlier to enroll patients in
the clinical trial and HMGA proteins expression. High-mobility
group A1 and 2 nuclear staining positively correlated with the
proliferation index in GEP NETs (R¼0.28, Po0.05; R¼0.434,
Po0.001; respectively). MIB-1 LI progressively increased following
HMGA1 and 2 expression score, although not significant (Figure 3I
and J). MIB-1 LI also progressively increased from WNETs to
WNECs and PNECs (Po0.001; Figure 3K) and following tumour
stage (Po0.05; Figure 3L). Furthermore, MIB-1 LI positively
correlated with tumour size (R¼0.409, Po0.005).
Between 6 GI WNETs with uncertain behaviour (41cm or
vascular invasion) and 14 GI WNETs with benign behaviour,
HMGA1 and 2 expressions did not show any significant differences
(data not shown). Although HMGA1 and 2 expressions were
potentially high in WNECs, there was no significant correlation
between HMGA proteins expression and tumour malignancy (i.e.,
WNETs vs WNECs) in foregut or hindgut NETs, respectively (data
not shown). We could not find any significant differences in
HMGA1 and 2 expression between PNEC areas and adenocarci-
noma areas in several PNEC cases (data not shown).
Insulinoma 
WNEC 
PNEC 
WNET
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Figure 2 Haematoxilin and eosin staining, high-mobility group A1 (HMGA1) and HMGA2 immunostaining figures of well-differentiated NET (WNET)
(A, E and I), insulinoma (B, F, and J), well-differentiated neuroendocrine carcinoma (WNEC) (C, G, and K), and poorly differentiated NEC (PNEC)
(D, H, and L), respectively. High-mobility group A1 (E–H) and HMGA2 (I–L) showed strongly nuclear immunostaining in gastroenteropancreatic
neuroendocrine tumours.
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sHMGA1 and 2 mRNA expression analysis by RT–PCR
In RT–PCR mRNA study, HMGA1 and 2 mRNA expression was
analysed on normal tissues from 7 organs (each organ sample pool
included RNA from four normal tissues) and 31 tumours with 25
surrounding non-tumour tissues. As shown in Figure 4C, HMGA1
and 2 mRNA amplification was not observed in normal organs.
Only a very weak band could be seen in colon and rectum.
However, in many tumours HMGA1 and 2 mRNA was abundantly
amplified, whereas their expression was not detected in surround-
ing non-tumour tissues (Table 1, Figure 4D and E). Generally, the
mRNA expression of HMGA1and 2 correlated well with the nuclear
expression of HMGA1 and 2 proteins as detected by IHC analysis
(Po0.0005, Po0.0005, respectively).
Table 1 Summary of characteristics of 55 GEP NETs and expressions of HMGA1, 2, and let-7
Number
Sex/
age Location Organ
Classi-
fication
Tumour
stage,
invasion,
or metastasis
Tumour
size
(cm)
MIB-1
LI (%)
HMGA1
IHC
(%)
HMGA1
mRNA
HMGA2
IHC
(%)
HMGA2
mRNA
let-7
tumour
let-7
non-
tumour
1 M/47 Hindgut Rectum WNET Stage Ia 0.4 0 5 ND 10 ND ND ND
2 M/40 Foregut Stomach WNET Stage I 0.9 0 0   10 + 0 0.71
3 M/75 Foregut Stomach WNET Stage 0 0.3 0 0 ND 18 ND ND ND
4 F/70 Foregut Stomach WNET Stage I 0.9 0 0   0   0 1.2
5 F/62 Hindgut Rectum WNET Stage Ib 1.2 0 5 + 10 + 0.48 0.53
6 F/62 Hindgut Rectum WNET Stage Ib 1.5 1 10 + 0   0.1 1.49
7 M/58 Foregut Stomach WNET Stage I 0.8 1 15 + 18 + 0.03 ND
8 M/62 Hindgut Rectum WNET Stage Ia, ly(+) 0.9 0 50 + 25 + 0 0.51
9 M/61 Hindgut Rectum WNET Stage IIa 2.2 0 15 + 0   0 1.22
10 F/67 Hindgut Rectum WNET Stage Ia 0.6 0 50 + 0 + 0.06 ND
11 M/56 Hindgut Rectum WNET Stage Ib, ly(+) 1 0 0 ND 0 ND ND ND
12 M/34 Hindgut Rectum WNET Stage Ia 0.6 0 70 ND 10 ND ND ND
13 M/46 Hindgut Rectum WNET Stage Ia 0.3 0 0   0   0 0.18
14 F/51 Hindgut Rectum WNET Stage Ia 0.8 1 10   10 + 0.3 ND
15 M/62 Hindgut Rectum WNET Stage Ia 0.5 1 20 + 10 + 0 0.47
16 M/70 Foregut Pancreas WNET Stage I 1 0.5 0 + 10 + 0 0.4
17 M/63 Foregut Pancreas WNET Stage I 1.1 0.5 50 + 50 + 0.22 1.4
18 M/63 Foregut Pancreas WNET Stage I 1.5 1 10 + 25 + 0.08 0.85
19 F/48 Foregut Pancreas WNET Stage I 1 0 20 + 50 + 0.3 0.34
20 M/74 Foregut Pancreas WNET Stage I 0.2 1 50 + 0 + 0 1.04
21 M/82 Foregut Pancreas WNET Stage I 1.1 0.5 0   25 + 0.09 0.97
22 M/49 Hindgut Rectum WNET Stage Ia 0.4 0.6 5   10 + 0 0.49
23 M/35 Hindgut Rectum WNET Stage Ib 1.4 0.4 5   10 + 0.12 0.94
24 F/57 Foregut Pancreas WNET Stage I 1.6 2 10 + 20 + 0.33 ND
25 F/38 Hindgut Colon WNET Stage Ia 0.2 0 15 ND 0 ND ND ND
26 F/61 Foregut Duodenum WNET Stage I 0.3 0.5 50 ND 65 ND ND ND
27 M/64 Foregut Duodenum WNET Stage I 0.5 0 100 ND 20 ND ND ND
28 M/53 Foregut Pancreas WNET Stage I 0.6 0.6 50 + 50 + 0.08 0.35
29 F/53 Foregut Pancreas WNET Stage I, v(+) 1.5 0 0   10 + 0.1 0.57
30 M/44 Hindgut Rectum WNEC Stage Ia 0.8 0 0 ND 0 ND ND ND
31 M/48 Foregut Metastasis WNEC Stage IIIb, ly(+), m(ln) 0.9 3 20 + 10 + 0.001 0.35
32 F/74 Midgut Appendix WNEC Stage IIa 1.3 0 0 ND 20 ND ND ND
33 F/69 Foregut Duodenum WNEC Stage IIIb, ly(+), m(ln) 4 0 50 ND 55 ND ND ND
34 F/63 Foregut Pancreas WNEC Stage IIa 3 0.5 5 ND 10 ND ND ND
35 M/82 Midgut Ileum caecum WNEC Stage IIa 2.4 0 20 ND 0 ND ND ND
36 M/53 Hindgut Metastasis WNEC Stage IIIb, ly(+), m(ln) 2.5 10 50 + 23 + 0.55 1.18
37 F/53 unknow Metastasis WNEC Stage IIIb, ly(+), m(ln) 1.9 10 10 + 85 + 0.19 ND
38 F/68 Foregut Duodenum WNEC Stage IIA 1.5 0 60 + 65 + 0 ND
39 M/66 Foregut Pancreas WNEC Stage IIb 7 5 0 + 0   0.03 1.56
40 M/56 Foregut Duodenum WNEC Stage IIIb, ly(+), m(ln) 1.3 50 90 ND 85 ND ND ND
41 F/40 Midgut Metastasis WNEC Stage IIIb, m(ln) 1.5 8 0 ND 0 ND ND ND
42 M/60 Midgut Ileum–caecum WNEC Stage I 0.6 2 0 ND 0 ND ND ND
43 M/50 Foregut Stomach PNEC Stage IIa 0.2 50 90 ND 90 ND ND ND
44 F/69 Foregut Stomach PNEC Stage IV, m(li) 0.2 15 50 ND 75 ND ND ND
45 F/62 Hindgut Rectum PNEC Stage IA 0.3 30 40 ND 100 ND ND ND
46 M/71 Hindgut Colon PNEC Stage IIIb, ly(+), v(+), m(ln) 7 30 0   10 + ND ND
47 F/53 Hindgut Sigmoid PNEC Stage IIa 2.3 50 20 + 26 + 0 0.07
48 M/72 Foregut Stomach PNEC Stage IIIa, ly(+), v(+) 4.5 0 0   65 + 0 0
49 M/69 Foregut Esophagus PNEC Stage IV, m(li) 4.5 50 50 ND 90 ND ND ND
50 F/60 Foregut Stomach PNEC Stage IIIb, ly(+), v(+), m(ln) 2.8 20 0 ND 0 ND ND ND
51 M/67 Foregut Stomach PNEC Stage IIIb, ly(+), v(+), m(ln) 7 10 20 ND 20 ND ND ND
52 M/63 Foregut Duodenum PNEC Stage IIIa, ly(+), v(+) 8 50 25 ND 35 ND ND ND
53 M/69 Foregut Stomach PNEC Stage IIIb, ly(+), m(ln) 5.5 25 50 ND 0 ND ND ND
54 M/74 Foregut Stomach PNEC Stage IIb, v(+) 5 50 5 ND 10 ND ND ND
55 M/57 Hindgut Colon PNEC Stage IIa, ly(+), v(+) 6 3 0   10   0.19 0.85
GEP¼gastroenteropancreatic; NET¼neuroendocrine tumour; WNET¼well-differentiated neuroendocrine tumour; WNEC¼well-differentiated neuroendocrine carcinoma;
PNEC¼poorly differentiated neuroendocrine carcinoma; v (+)¼vascular invasion; ly (+)¼lymph vessels invasion; m¼metastasis; ln¼lymph node; li,¼liver; tumour¼tumour
tissue only; non-tumour¼tumour margin non-tumour tissue.
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Semiquantitative RT–PCR method was used to address the levels
of let-7 in normal tissues from six organs including stomach,
pancreas, duodenum, small intestine, appendix, and colon (each
organ sample pool included RNA from four normal tissues).
Normal pituitary, used as positive control, expressed easily
detectable levels of let-7 (let-7/U6, 0.9) (Figure 5A). Other normal
samples from six organs showed moderate levels of let-7 (let7/U6,
0.21–0.24) (Figure 5A). This difference may relate to tissue
specificity. In tumour margin tissue samples, 22 of 24 cases
expressed high levels of let-7 (let-7/U6, 0.33–1.49) (Table 1,
Figure 5B). On the basis of the above observation, we arbitrarily
classified expression levels of less than one-half of let-7 value in
normal tissues, that is, let-7/U6 o0.1 as significant reduction.
Thus, downregulated expression of let-7 was found in 19 of
30 (63%) tumours (negative, 11; significantly reduction, 9). The
average levels of let-7 expression were significantly lower in GEP
NETs than normal organs and their surrounding non-tumour
tissues (Figure 5C). Let-7 expression was not significantly different
among WNETs, WNECs, and PNECs (Figure 5C, Table 3).
We also investigated the relationship between let-7 expression
and HMGA1, 2 proteins expression in 30 GEP NETs through
several viewpoints. High-mobility group A1 high expression was
more frequently detected in 19 tumours with significant let-7
downregulation (53%) than in tumours with regular level of let-7
expression (Po0.05). The average level of let-7 expression was
lower in NETs with HMGA1 overexpression than in tumours with
negative or moderate expression of HMGA1 (data not shown).
These data implied that there might be inverse correlation between
the expression of let-7 and HMGA1. Unfortunately, we could not
observe the clear inverse correlation between the expression of
let-7 and HMGA2 protein expression, although high expression of
HMGA2 was frequently detected in tumours with significant
downregulation of let-7 (42%). When analysed the relation
between clinicopathological characteristics of 30 GEP NETs and
reduced let-7 expression, there were no notable differences in
patient age, sex, tumour size, vascular invasion, or tumour
metastasis (data not shown).
DISCUSSION
Gastroenteropancreatic NETs originate from the cells of the diffuse
endocrine system. The molecular genetic mechanism of develop-
ment and progression is complex and remains largely unknown.
Gastroenteropancreatic NETs do not show alterations in onco-
genes, such as ras, myc, fos jun, and src, or in common tumour
suppressor genes (Delle Fave and Corleto, 2001). High-mobility
group A1 and 2 have been detected in many kinds of benign and
malignant tumours (Fusco and Fedele, 2007). Interestingly, over-
expression of HMGA1 and 2 also has been shown in NETs
including small cell carcinomas and pituitary adenomas (Brenner
et al, 2004; Fusco and Fedele, 2007). These findings enhanced us to
investigate the role of HMGA1 and 2 protein in GEP NETs
tumourigenesis and progression.
Our study is the first time to characterise HMGA1 and 2
overexpression in GEP NETs. We found that HMGA1 and 2
overexpression was a common event in GEP NETs. Notably, a high
level overexpression of HMGA1 and 2 was frequently observed in
WNETs as in WNECs and PNECs. High-mobility group A proteins
contributed to tumourigenesis in various benign human tumours
including lipomas, uterine leiomyomas, and pituitary adenomas.
Little is known about pathogenesis of sporadic WNETs (Zikusoka
et al, 2005). Our findings suggested that HMGA proteins might
relate to the tumourigenesis of GEP NETs.
High-mobility group A1 and 2 interact with many different
transcription factors and influence numerous gene expression
patterns. They are important regulators of cell growth, differentia-
tion, apoptosis, and transformation (Reeves, 2001). It has been
shown that a high expression of HMGA1 and 2 is associated with a
highly malignant phenotype and is a poor prognostic index (Fusco
and Fedele, 2007). The expression of HMGA1 differed from the
expression of HMGA2 in GEP NETs only with respect to the
correlation of expression with histopathologic categories. High-
mobility group A2 protein expression increased from WNETs to
WNECs and PNECs and from stages I, II, III tumours to stage IV
tumours. Interestingly, both HMGA1 and 2 overexpression may
relate to tumour metastasis in WNECs. Furthermore, we observed
the correlation between cell proliferation marker MIB-1 LI and
HMGA protein overexpression. Because more than a half of GEP
NETs are functionally inactive and are usually diagnosed once
signs and symptoms of tumour metastasis occur (Oberg, 2002), the
distinction benign and malignant GEP NET is very important.
However, it has not been completely resolved (Rindi and Bordi,
2005). Our data implied that HMGA proteins may reliably predict
the course of this disease and may have prognostic significances in
GEP NETs. However, the exact mechanism involving in HMGA
oncogenic activity in GEP NET needs further investigation.
Table 2 HMGA1 and 2 proteins expression in GEP NETs and clinicopathologic associations
No. of cases
HMGA1 expression HMGA2 expression
Variable 55 Negative (n¼17) Low (n¼11) High (n¼27) Negative (n¼15) Low (n¼15) High (n¼25)
Age (year) 60.9 56.2 60.3 59.8 54.2 62.4
Gender
Female 20 5 (25%) 6 (30%) 9 (45%) 6 (30%) 4 (20%) 10 (50%)
Male 35 12 (34%) 5 (14%) 18 (52%) 9 (26%) 11 (31%) 15 (43%)
Histologic type
WNET 29 8 (27.5%) 8 (27.5%) 13 (45%) 8 (27.5%) 10 (34.5%) 11(38%)
WNEC 13 5 (39%) 2(15%) 6 (46%) 5 (39%) 2 (15%) 6 (46%)
PNEC 13 4 (30%) 1 (8%) 8 (62%) 2 (15%) 3 (23%) 8 (62%)
Site
Foregut 30 9 (30%) 4 (13%) 17 (57%) 5 (17%) 6 (20%) 19 (63%)*
Hindgut 21 5 (24%) 7 (33%) 9 (43%) 7 (33%) 9 (43%) 5 (24%)
Midgut 4 3 (75%) 0 1(25%) 3 (75%) 0 1 (25%)
GEP¼gastroenteropancreatic; NET¼neuroendocrine tumour; WNET¼well-differentiated neuroendocrine tumour; WNEC¼well-differentiated neuroendocrine carcinoma;
PNEC¼poorly differentiated neuroendocrine carcinoma. Negative¼0; Low¼1+; High¼2+ and 3+; (0: no expression; 1+: 1–10%; 2+: 10–50%; 3+: 450%). *Po0.05.
HMGA oncoproteins overexpression in GEP NETs
MM Rahman et al
506
British Journal of Cancer (2009) 100(3), 501–510 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
Without 
metastasis
With 
metastasis
Without 
metastasis
With 
metastasis
WNEC WNEC
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
WNET
NS
NS NS
NS
NS NS
P< 0.005
P< 0.05
P< 0.05 P<0.05
WNEC PNEC WNET WNEC PNEC
H
M
G
A
1
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
H
M
G
A
1
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
H
M
G
A
1
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
H
M
G
A
2
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
H
M
G
A
2
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
H
M
G
A
2
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
Foregut Hindgut Midgut 
Foregut Hindgut Midgut 
A B C
DE F
0.60 NS NS
NS
Stage I Stage II Stage III Stage IV
Stage I Stage II Stage IIIStage IV
Stage I Stage II Stage III Stage IV
0.50
0.40
0.30
0.20
0.10
0.00
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.60
P<0.05
P<0.001
P<0.01
0.50
0.40
0.30
0.20
0.10
0.00
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
0.18
0 1+ 2+, 3+
WNET WNEC PNEC 0 1+ 2+, 3+
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
H
M
G
A
1
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
HMGA1 expression
HMGA2 expression
M
I
B
-
1
 
L
I
 
(
%
)
M
I
B
-
1
 
L
I
 
(
%
)
M
I
B
-
1
 
L
I
 
(
%
)
M
I
B
-
1
 
L
I
 
(
%
)
H
M
G
A
2
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
GH I
JK L
Figure 3 The relations between expression levels of high-mobility group A (HMGA1), HMGA2 proteins and clinicopathologic data of
gastroenteropancreatic (GEP) neuroendocrine tumours (NETs). According to different histopathologic categories, HMGA1 protein expression did not
show significant difference among well-differentiated NET (WNET), well-differentiated neuroendocrine carcinoma (WNEC), and poorly differentiated NEC
(PNEC) (A). High-mobility group A2 protein expression increased from WNET to WNEC and PNEC, and its significant difference was observed between
WNET and PNEC (Po0.005) (B). Gastroenteropancreatic NETs in foregut showed the highest level of HMGA1 expression but it was not significant (C).
Gastroenteropancreatic NETs of foregut also showed the highest level of HMGA2 expression (Po0.05) (D). In GEP WNECs, the expression of HMGA1
and 2 was higher in metastasis tumours than in tumours without metastasis (Po0.05, Po0.05) (E and F). High-mobility group A1 protein expression
increased following tumour stage but did not show significant difference (G). High-mobility group A2 protein showed the highest level in stage IV GEP NETs
(Po0.01) (H). MIB LI progressively increased following HMGA1 and 2 expression score, although it was not significant (I and J). MIB-1 LI progressively
increased from WNETs to WNECs and PNECs (Po0.001) (K), and following tumour stage (Po0.05) (L).
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sThe current literature suggests that several genes are involved in
GEP NET tumourigenesis with significant differences among
tumours of different embryological derivatives: foregut, midgut,
and hindgut. The MEN1 gene is involved in initiation of 33% of
foregut GEP NETs (Lubensky and Zhuang, 2007). 18q defects are
present almost exclusively in mid/hindgut NETs (Lubensky and
Zhuang, 2007). X-chromosome markers are associated with
malignant behaviour in foregut tumours only (Lubensky and
Zhuang, 2007). In this study, GEP NETs in foregut showed the
highest level of HMGA1 and 2 proteins expression. However, the
differences in HMGA protein expression among tumour sites need
further investigation in large series of GEP NETs.
Recent studies have shown that let-7 plays a role as tumour
suppressors by negatively regulating expression of RAS and
HMGA2 oncogenes (Johnson et al, 2005; Hebert et al, 2007; Mayr
et al, 2007; Wang et al, 2007). Let-7 downregulation is commonly
seen in neoplasm, including lung, breast and gastric cancers, and
uterine leiomyomas (Takamizawa et al, 2004; Iorio et al, 2005;
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Figure 4 Pre-microdissection figure of one well-differentiated neuroendocrine tumour (WNET) (A). Post-microdissection figure of the same WNET (B).
High-mobility group A1 (HMGA1) (133bp) and HMGA2 (155bp) mRNA amplification were not observed in normal tissues. In colon and rectum, a very
weak band was detected (C). But in tumours, HMGA1 (D) and 2 (E) mRNA was abundantly amplified, whereas their expressions were not detected in
tumour margin non-tumour tissues. GAPDH (375bp) expression was used as endogenous control for RNA integrity.
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sWang et al, 2007; Motoyama et al, 2008). In this study, we observed
that let-7 downregulation is very common from benign NETs to
small cell carcinomas. This is the first finding that aberrant
expression of let-7 may relate to GEP NET tumourigenesis.
Furthermore, the reverse correlation between let-7 downregulation
and HMGA1 overexpression has been first observed in tumours.
Till now, the mechanism of HMGA1 overexpression is not clear
and many studies only focus on HMGA2 regulated by let-7 family
(Takamizawa et al, 2004; Iorio et al, 2005; Wang et al, 2007;
Motoyama et al, 2008). Our findings implied that loss or reduction
of let-7 might be one potential mechanism of HMGA1 protein
overexpression. On the other hand, although the clearly reverse
correlation between let-7 downregulation and HMGA2 over-
expression was not detected in this small series of GEP NETs,
loss and reduction of let-7 expression may also be one important
mechanism of HMGA2 overexpression. The truncated transcripts
of HMGA2 with a partial or complete loss of let-7 complementary
sites can explain the increased expression of HMGA2 in tumours
with slight reduction or regular level of let-7 expression (Fusco and
Fedele, 2007). In addition, by computer searches, we found that
HMGA1 and 2 can be potentially regulated by many other
miRNAs. Further investigation of miRNAs would be important
in GEP NET tumourigenesis study.
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Figure 5 Semiquantitative reverse transcription–PCR method was used to address the levels of let-7 in normal tissues from 6 organs (stomach, pancreas,
duodenum, small intestine, appendix, and colon), 30 gastroenteropancreatic neuroendocrine tumours (NETs), and their margin non-tumour tissues. Normal
pituitary tissue was used as positive control. U6 expression was used as endogenous control for small RNA integrity and as templates for quantitative
analysis. Generally, normal tissues from different organs clearly showed let-7 expression (A). Comparing with the level of let-7 expression in tumour’s margin
non-tumour tissues, negative or reduced expression of let-7 was detected in tumours (B). The average level of let-7 expression was significantly lower in
well-differentiated NET (WNETs), well-differentiated NECs (WNECs), and poorly differentiated NEC (PNECs) than in their margin non-tumour tissues and
in normal organs (*Po0.05). Interestingly, the let-7 expression was higher in tumour’s margin non-tumour tissues than in normal organs. In addition, let-7
expression was not significantly different among WNETs, WNECs, and PNECs (C).
Table 3 let-7 expression in GEP NETs
let-7 expression
Variable Case numbers 30  , ± (n¼19) + (n¼11) P-value
HMGA1
Negative 9 7 (36%) 2 (18%) o0.05
Low 8 2 (11%) 6 (55%)
High 13 10 (53%) 3 (27%)
HMGA2
Negative 7 6 (31%) 1 (9%) 0.31
Low 10 5 (26%) 5 (45.5%)
High 13 8 (42%) 5 (45.5%)
Histologic type
WNET 22 14 (64%) 8 (36%) 0.98
WNEC 5 3 (60%) 2 (40%)
PNEC 3 2 (66.6%) 1 (33.3%)
GEP¼gastroenteropancreatic; NET¼neuroendocrine tumour; WNET¼well-
differentiated neuroendocrine tumour; WNEC¼well-differentiated neuroendocrine
carcinoma; PNEC¼poorly differentiated neuroendocrine carcinoma;  ¼negative;
±¼significant downregulation; +¼normal level; Negative¼0; Low¼1+;
High¼2+ and 3+.
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sSeveral studies have aimed to develop cancer therapy by
inhibiting HMGA proteins (Scala et al, 2000). In pancreatic
adenocarcinoma, blocking HMGA protein synthesis has a negative
effect on tumour cell proliferation and metastatic potential (Liau
et al, 2006). The differential expression of HMGA1 and 2 in GEP
NETs and normal cells should allow for the specificity and lower
toxicity of such therapy. Furthermore, as HMGA1 and 2 proteins
are frequently overexpressed in GEP NETs, HMGA-targeted
anticancer therapy could have a wide ranged application.
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